Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
2.60
Dollar change
-0.29
Percentage change
-10.16
%
Index- P/E- EPS (ttm)-47.62 Insider Own66.82% Shs Outstand1.61M Perf Week-0.38%
Market Cap4.19M Forward P/E- EPS next Y- Insider Trans-0.14% Shs Float0.53M Perf Month-0.19%
Income-76.35M PEG- EPS next Q- Inst Own12.17% Short Float2.19% Perf Quarter-26.55%
Sales0.11M P/S38.06 EPS this Y- Inst Trans116.51% Short Ratio0.62 Perf Half Y-53.07%
Book/sh14.25 P/B0.18 EPS next Y- ROA-61.68% Short Interest0.01M Perf Year-76.58%
Cash/sh15.60 P/C0.17 EPS next 5Y41.70% ROE-128.75% 52W Range2.19 - 16.74 Perf YTD-27.98%
Dividend Est.- P/FCF- EPS past 5Y-37.86% ROI-148.85% 52W High-84.47% Beta0.48
Dividend TTM- Quick Ratio6.33 Sales past 5Y-16.71% Gross Margin-1320.56% 52W Low18.72% ATR (14)0.33
Dividend Ex-Date- Current Ratio6.33 EPS Y/Y TTM33.95% Oper. Margin-33265.42% RSI (14)48.07 Volatility11.21% 12.94%
Employees1 Debt/Eq1.32 Sales Y/Y TTM-87.57% Profit Margin-71351.40% Recom1.00 Target Price10.00
Option/ShortNo / Yes LT Debt/Eq1.24 EPS Q/Q88.80% Payout- Rel Volume0.85 Prev Close2.89
Sales Surprise- EPS Surprise-1377.78% Sales Q/Q-100.00% Earnings- Avg Volume18.64K Price2.60
SMA20-2.62% SMA50-2.97% SMA200-47.78% Trades Volume15,848 Change-10.16%
Date Action Analyst Rating Change Price Target Change
Aug-09-22Initiated H.C. Wainwright Buy $17
Apr-13-21Initiated Jefferies Buy $29
Apr-13-21Initiated Evercore ISI Outperform $34
Apr-13-21Initiated BofA Securities Buy $25
Mar-25-24 09:52PM
Nov-22-23 09:14AM
Jun-09-23 07:00AM
May-11-23 05:05AM
May-10-23 07:00AM
04:05PM Loading…
Apr-25-23 04:05PM
Apr-18-23 04:01PM
Mar-25-23 09:34AM
Mar-23-23 04:05PM
Jan-24-23 01:53PM
10:55AM
08:00AM
Nov-10-22 08:15AM
07:00AM
Nov-09-22 08:00AM
08:00AM Loading…
Oct-24-22 08:00AM
Sep-05-22 12:00PM
Sep-01-22 02:23PM
08:00AM
05:32AM
Aug-26-22 07:37AM
Aug-25-22 04:30PM
Aug-11-22 07:00AM
Aug-10-22 08:06AM
Jul-20-22 09:48AM
Jun-02-22 07:00AM
May-17-22 08:00AM
May-16-22 07:00AM
May-09-22 08:22AM
Apr-29-22 12:10PM
05:20PM Loading…
Apr-28-22 05:20PM
Apr-20-22 12:33PM
Apr-19-22 02:08PM
08:30AM
Mar-31-22 04:56PM
Mar-19-22 08:04AM
Mar-01-22 04:30PM
Feb-23-22 07:00AM
Feb-10-22 07:00AM
Jan-18-22 05:38PM
Jan-06-22 07:00AM
Jan-04-22 07:00AM
Dec-23-21 04:38AM
Dec-20-21 07:00AM
Dec-17-21 06:31AM
Nov-11-21 07:00AM
Nov-10-21 07:15AM
07:05AM
07:00AM
Nov-09-21 04:30PM
Oct-25-21 07:00AM
Oct-18-21 08:58AM
Oct-12-21 07:00AM
Oct-05-21 07:00AM
Sep-08-21 07:00AM
Sep-07-21 07:00AM
Aug-18-21 08:54AM
Aug-10-21 03:54PM
07:05AM
07:00AM
Jun-28-21 07:00AM
May-28-21 07:00AM
May-13-21 07:00AM
May-06-21 07:00AM
Apr-27-21 07:00AM
Mar-19-21 04:25PM
Mar-18-21 10:32PM
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in 2014 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SMISEK JEFFERY ADirectorNov 22 '23Sale3.641,4705,3516,642Nov 27 04:54 PM
Graf Susan EDirectorJun 09 '23Buy0.275,0101,3535,010Jun 09 04:15 PM